DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Radiolabeled PARP Inhibitors for Imaging and Targeted Radiotherapy of Prostate Cancer
[Technical Report, Annual Report]
WASHINGTON UNIV ST LOUIS MO
Pagination or Media Count:
The of this grant is to investigate a 77Br-labeled polyADP-ribose polymerase-1 PARP-1 inhibitor for Augerradiation targeted radiotherapy of mCRPC. PARP-1 is a nuclear enzyme which initiates DNA repair by binding tothe sites of single- or double-strand breaks SSBDSB. The major goals of this reporting period were to 1.Determine the maximum tolerated dose and toxicity of 77BrWC-DZ-Br, 2. Conduct single dose therapy studies of77BrWC-DZ-Br in tumor bearing mice, 3. determine the dosimetry of 77BrWC-DZ-Br in normal mice, and 4. Starttherapy in a metastatic model. The major activities conducted in this reporting period were to evaluate 77BrWCDZ-Br in vivo to determine its therapeutic efficacy and toxicity after a single administration. The significant results ofthis reporting period were that 77BrWC-DZ-Br was relatively non-toxic in mice and that it demonstrated significanttumor growth delay in mice bearing subcutaneous PC-3 and IGR-CaP1 tumors. In addition, we have madeprogress in establishing the metatstatic IGR-CaP1 model.
[A, Approved For Public Release]